Stocktoria

BIOGEN INC. BIIB

Nasdaq · stock · Biological Products, (No Diagnostic Substances) · website · IPO 1991-09-17 · LEI

BIOGEN INC. statistics & valuation

Market cap$31.9B
P / E24.7×
P / S3.2×
P / B1.7×
P / FCF15.6×
Net margin13.1%
Return on equity7.1%
FCF margin20.7%
Net debt$6.3B
Enterprise value USD$38.2B
Graham number -25%$156.67

Market cap as of 2026-06-29. Multiples are price-derived and refreshed daily; everything else from the latest financial reports. The Graham number is Benjamin Graham's rough maximum fair value ($156.67); a green figure means the price is below it.

Profitability & efficiency

Net margin (%)
32.30% 20.70% 32.90% 41.00% 29.80% 14.20% 29.90% 11.80% 16.90% 13.10% 2016201720182019202020212022202320242025
Gross margin (%)
87.10% 86.70% 86.50% 86.40% 86.60% 2016201720182019202020212022202320242025
Operating margin (%)
45.00% 43.60% 43.80% 49.00% 33.80% 25.90% 2016201720182019202020212022202320242025
Return on equity (%)
30.50% 20.10% 34.00% 44.10% 37.40% 14.20% 22.70% 7.80% 9.80% 7.10% 2016201720182019202020212022202320242025
Shares outstanding
218.8M 213.0M 205.3M 187.4M 161.3M 149.6M 146.0M 145.6M 145.9M 147.1M 2016201720182019202020212022202320242025
Net debt ($)
$4.19B $4.36B $4.71B $1.55B $7.43B $6.27B $6.28B $6.79B $4.55B $6.29B 2016201720182019202020212022202320242025
Share buybacks ($)
2016201720182019202020212022202320242025
Return on assets (%)
16.20% 10.70% 17.50% 21.60% 16.30% 6.50% 12.40% 4.30% 5.80% 4.40% 2016201720182019202020212022202320242025
Free cash flow margin (%)
34.70% 30.00% 40.30% 45.70% 28.30% 30.80% 11.20% 12.90% 28.10% 20.70% 2016201720182019202020212022202320242025
Debt / equity (×)
0.54× 0.47× 0.46× 0.33× 0.69× 0.57× 0.47× 0.46× 0.27× 0.34× 2016201720182019202020212022202320242025
EPS ($)
$16.93 $11.92 $21.58 $31.42 $24.80 $10.40 $20.87 $7.97 $11.18 $8.79 2016201720182019202020212022202320242025

Margins and returns computed from annual filings. Falling shares outstanding = buybacks; rising = dilution. Net debt = debt − cash (negative = net cash).

P / E vs its own history

BIOGEN INC. trades at about 23.8× earnings — above its 10-year norm (10-year range 8.6×–30.9×, median 16.4×).

8.6× 30.9×

Shaded band = 10-year range (8.6×–30.9×); dot = today's 23.8×.

Historical P/E = month-end price near each fiscal year-end ÷ that year's EPS. A read on whether the stock is cheap or dear relative to how it has typically been valued — not a forecast.

Key ratios (by fiscal year)

RatioFY2025FY2024FY2023FY2022FY2021FY2020FY2019FY2018FY2017FY2016
Gross margin—————86.6%86.4%86.5%86.7%87.1%
Operating margin————25.9%33.8%49.0%43.8%43.6%45.0%
Net margin13.1%16.9%11.8%29.9%14.2%29.8%41.0%32.9%20.7%32.3%
FCF margin20.7%28.1%12.9%11.2%30.8%28.3%45.7%40.3%30.0%34.7%
Return on assets4.4%5.8%4.3%12.4%6.5%16.3%21.6%17.5%10.7%16.2%
Return on equity7.1%9.8%7.8%22.7%14.2%37.4%44.1%34.0%20.1%30.5%
Debt / equity0.34×0.27×0.46×0.47×0.57×0.69×0.33×0.46×0.47×0.54×
Current ratio2.681.352.002.991.831.841.722.322.342.55

Computed from company filings · US · as of 2025-12-31. Facts plus Stocktoria's own computed scores — not investment advice.